Cardiovascular Diseases

At Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta, the main focus is cardiovascular research, with trials studying acute myocardial infarction, atrial fibrillation, atherosclerosis, and broader cardiovascular disease. These studies are designed to assess whether new approaches can better prevent major heart and blood vessel events, improve stroke prevention, and reduce future complications in people at high risk.

  • Testing new treatments to lower the risk of major adverse cardiovascular events
  • Evaluating therapies for stroke and systemic embolism prevention in atrial fibrillation
  • Studying options for people recovering from or at risk of acute myocardial infarction

Much of the work in this area also explores primary prevention and risk reduction in patients with elevated cardiovascular risk, including those with elevated lipoprotein(a).

Nutritional and Metabolic Diseases

The site is also active in nutritional and metabolic research, especially studies on hypertriglyceridemia and related atherosclerotic cardiovascular disease. These trials aim to understand whether targeted therapies can improve lipid levels and help lower long-term cardiovascular risk.

  • Assessing treatments for high triglycerides
  • Exploring ways to reduce cardiovascular risk linked to abnormal lipid profiles
  • Supporting prevention strategies for patients with metabolic risk factors

This research reflects a strong interest in connecting metabolic health with heart disease prevention.

Musculoskeletal Diseases

Clinical trials in musculoskeletal disease at this hospital include research on moderate to severe rotator cuff tendinopathy. The goal is to evaluate whether new treatment options can improve shoulder pain, function, and day-to-day mobility for people affected by chronic tendon injury.

  • Improving shoulder symptoms and physical function
  • Testing therapies for persistent tendon-related pain
  • Studying better care options for upper limb mobility problems

Although smaller in scope than the cardiovascular portfolio, this work broadens the site’s clinical research profile beyond heart disease.